0001209191-20-063343.txt : 20201214
0001209191-20-063343.hdr.sgml : 20201214
20201214192012
ACCESSION NUMBER: 0001209191-20-063343
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201210
FILED AS OF DATE: 20201214
DATE AS OF CHANGE: 20201214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rhodes Jason P
CENTRAL INDEX KEY: 0001577014
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38596
FILM NUMBER: 201387764
MAIL ADDRESS:
STREET 1: C/O EPIZYME, INC.
STREET 2: 400 TECHNOLOGY SQUARE, 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Replimune Group, Inc.
CENTRAL INDEX KEY: 0001737953
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 822082553
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
BUSINESS PHONE: (781) 222-9600
MAIL ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-10
0
0001737953
Replimune Group, Inc.
REPL
0001577014
Rhodes Jason P
18 COMMERCE WAY
WOBURN
MA
01801
1
0
0
0
Common Stock
2020-12-10
4
S
0
12691
42.68
D
2371734
I
See Footnote
Common Stock
2020-12-10
4
S
0
8666
43.48
D
2363068
I
See Footnote
Common Stock
2020-12-10
4
S
0
2653
44.35
D
2360415
I
See Footnote
Common Stock
2020-12-10
4
S
0
4389
42.68
D
988942
I
See Footnote
Common Stock
2020-12-10
4
S
0
2996
43.48
D
985946
I
See Footnote
Common Stock
2020-12-10
4
S
0
917
44.35
D
985029
I
See Footnote
Common Stock
2020-12-10
4
S
0
1099
42.68
D
28649
I
See Footnote
Common Stock
2020-12-10
4
S
0
750
43.48
D
27899
I
See Footnote
Common Stock
2020-12-10
4
S
0
230
44.35
D
27669
I
See Footnote
Common Stock
2020-12-11
4
S
0
19712
43.32
D
2340703
I
See Footnote
Common Stock
2020-12-11
4
S
0
2374
43.92
D
2338329
I
See Footnote
Common Stock
2020-12-11
4
S
0
6817
43.32
D
978212
I
See Footnote
Common Stock
2020-12-11
4
S
0
821
43.92
D
977391
I
See Footnote
Common Stock
2020-12-11
4
S
0
1707
43.32
D
25962
I
See Footnote
Common Stock
2020-12-11
4
S
0
205
43.92
D
25757
I
See Footnote
Common Stock
2020-12-14
4
S
0
2776
42.69
D
2335553
I
See Footnote
Common Stock
2020-12-14
4
S
0
21428
43.54
D
2314125
I
See Footnote
Common Stock
2020-12-14
4
S
0
2087
44.06
D
2312038
I
See Footnote
Common Stock
2020-12-14
4
S
0
961
42.69
D
976430
I
See Footnote
Common Stock
2020-12-14
4
S
0
7409
43.54
D
969021
I
See Footnote
Common Stock
2020-12-14
4
S
0
722
44.06
D
968299
I
See Footnote
Common Stock
2020-12-14
4
S
0
240
42.69
D
25517
I
See Footnote
Common Stock
2020-12-14
4
S
0
1855
43.54
D
23662
I
See Footnote
Common Stock
2020-12-14
4
S
0
181
44.06
D
23481
I
See Footnote
Shares were sold pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.15 to $43.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (8), (9), (10), (11) and (12).
The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.15 to $44.11 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.15 to $44.46 inclusive.
The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any.
The shares are held directly by AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims beneficial ownership of such securities held by AVA X LP, except to the extent of his pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.72 to $43.71 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.725 to $44.18 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.98 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.99 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.00 to $44.13 inclusive.
/s/ Ommer Chohan, Attorney-in-Fact
2020-12-14